TREATMENT.COM AI INC. ANNOUNCES UPSIZE ON LISTED ISSUER FINANCING EXEMPTION (LIFE) BOUGHT DEAL PRIVATE PLACEMENT

Date/time : 2025-03-03 07:00 AM
Symbol :

TRUE

Company : Treatment Com AI Inc Com
Price : 0.465
Market cap : 22,780,286
O/S : 48,989,862
Exchange :

CSE

Industry :

Healthcare Information Services

Full story

TREATMENT.COM AI INC. ANNOUNCES UPSIZE ON LISTED ISSUER FINANCING EXEMPTION (LIFE) BOUGHT DEAL PRIVATE PLACEMENT

Not for distribution to United States newswire services or for release publication, distribution, or dissemination directly, or indirectly, in whole or in part, in or into the United States

Vancouver, British Columbia, March 03, 2025 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (the “ Company ” or “ Treatment ”) (CSE: TRUE; OTC: TREIF; FFA: 939) is pleased to announce that due to high demand it has upsized the previously announced brokered private placement of units of the Company (the “ Offering ”) with Ventum Financial Corp., as underwriter to $3.30 million in gross proceeds with a 15% over-allotment option. The Company has filed an amended and restated offering document to reflect the upsize. Such amended and restated offering document is accessible under the Company’s profile at www.sedarplus.ca and on the Company’s website at www.treatment.com. Prospective investors should read this offering document before making an investment decision.

The securities issued pursuant to the Offering have not, nor will they be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons in the absence of U.S. registration or an applicable exemption from the U.S. registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful.

About Treatment.com AI Inc.

Treatment.com AI is a company utilizing AI and best clinical practices to positively improve the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, Treatment has built a comprehensive, personalized healthcare AI engine, the Global Library of Medicine (GLM). With more than ~10,000 expert medical reviews, the GLM delivers tested clinical information and support to all healthcare professionals, as well as providing recommended tests (physical and lab), x-rays, and billing codes. The GLM helps healthcare professionals (doctor, nurse or pharmacist) reduce their administrative burden; create more time for needed face to face patient appointments and enables greater consistency in quality of patient support. Treatment’s GLM platform, through supporting healthcare professionals, allows for the inclusion of disenfranchised communities. To learn more about Treatment’s products and services: www.treatment.com or email: info@treatment.com

FOR ADDITIONAL INFORMATION, CONTACT:

Dr. Essam Hamza, CEO
ehamza@treatment.com
For media inquiries, contact: media@treatment.com
Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955

Cautionary Statement

This news release contains forward-looking statements relating to the Offering and to future operations of Treatment and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, any statements regarding the closing of the Offering, the use of proceeds of the Offering, and future plans and objectives of Treatment, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Treatment's expectations include, amongst other things, failure to complete the Offering, the need to satisfy regulatory and legal requirements with respect to the Offering and other risks detailed from time to time in the filings made by Treatment with securities regulators.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Treatment. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Treatment will only update or revise publicly the included forward-looking statements as expressly required by Canadian securities law.


 

Primary Logo